Literature DB >> 16941154

Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.

Octavio Burgues1, Samuel Navarro, Rosa Noguera, Antonio Pellín, Amparo Ruiz, Victoria Castel, Antonio Llombart-Bosch.   

Abstract

In addition to clinical and biological factors, further valuable prognostic information in neuroblastoma (Schwannian stroma-poor) (NB) patients is provided by the histopathologic analysis and the application of the International Neuroblastoma Pathology Classification (INPC) system. The objective of this study was to assess the prognostic impact of the INPC classification in a series of NB (Schwannian stroma-poor) and its relation with other prognostic factors. One hundred eighty-two cases of NB were collected from the files of the Spanish Neuroblastoma Registry. Slides were reviewed, and NB cases were grouped into favorable and unfavorable categories according to INPC criteria, taking into account morphological features (mitosis-karyorrhexis index, histological subtype) and patient's age at diagnosis. Other pathological [presence of calcifications, tissular components, and number of mitotic cells per 10 high-power field (HPF)], immunohistochemical (P-glycoprotein and Ki-67 protein expression) and genetic (MYCN amplification and chromosome 1p deletion) features were also studied. Statistical analyses of overall survival with Kaplan-Meier curves and a multivariate study using Cox regression were performed (40.3% of NBs were considered favorable and 59.7% unfavorable). Unfavorable NB showed a mean survival time of 57 months compared with 89 months in favorable cases. Advanced stage, more than ten mitoses per 10 HPF, Ki-67 expression in more than 30% of tumor cells, MYCN oncogene amplification and chromosome 1p deletion were observed more frequently in unfavorable NB. The Cox regression analysis demonstrated that clinical stage (International Neuroblastoma Staging System stage 4) and histological subtype (undifferentiated NB) were the most important factors that influence the overall survival (p<0.001). INPC classification results are major prognostic indicators in NB and should be considered in the therapeutic stratification of NB patients.

Entities:  

Mesh:

Year:  2006        PMID: 16941154     DOI: 10.1007/s00428-006-0253-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  51 in total

Review 1.  Neuroblastoma. Pathology and biology.

Authors:  H Shimada
Journal:  Acta Pathol Jpn       Date:  1992-04

Review 2.  Monoclonal antibody Ki-67: its use in histopathology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1990-12       Impact factor: 5.087

Review 3.  Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.

Authors:  R E George; S Variend; C Cullinane; S J Cotterill; A G McGuckin; C Ellershaw; J Lunec; A D Pearson
Journal:  Med Pediatr Oncol       Date:  2001-01

4.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

5.  Evaluation of Ki-67 reactivity in neuroblastoma using paraffin embedded tissue.

Authors:  D Graham; H Magee; B Kierce; R Ball; P Dervan; A O'Meara
Journal:  Pathol Res Pract       Date:  1995-03       Impact factor: 3.250

6.  Telomerase activity distinguishes between neuroblastomas with good and poor prognosis.

Authors:  C Poremba; H Willenbring; B Hero; H Christiansen; K L Schäfer; C Brinkschmidt; H Jürgens; W Böcker; B Dockhorn-Dworniczak
Journal:  Ann Oncol       Date:  1999-06       Impact factor: 32.976

7.  Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma.

Authors:  H Caron
Journal:  Med Pediatr Oncol       Date:  1995-04

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Prognostic factor in neuroblastoma.

Authors:  A E Evans; G J D'Angio; K Propert; J Anderson; H W Hann
Journal:  Cancer       Date:  1987-06-01       Impact factor: 6.860

10.  Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

Authors:  H Shimada; D O Stram; J Chatten; V V Joshi; Y Hachitanda; G M Brodeur; J N Lukens; K K Matthay; R C Seeger
Journal:  J Natl Cancer Inst       Date:  1995-10-04       Impact factor: 13.506

View more
  11 in total

1.  TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.

Authors:  Yania Yáñez; David Hervás; Elena Grau; Silvestre Oltra; Gema Pérez; Sarai Palanca; Mar Bermúdez; Catalina Márquez; Adela Cañete; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-24       Impact factor: 4.553

2.  The many faces of atypical Ewing's sarcoma. A true entity mimicking sarcomas, carcinomas and lymphomas.

Authors:  Isidro Machado; Rosa Noguera; Eduardo Alcaraz Mateos; Silvia Calabuig-Fariñas; F Ignacio Aranda López; Antonio Martínez; Samuel Navarro; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2010-12-23       Impact factor: 4.064

3.  Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.

Authors:  Yania Yáñez; Elena Grau; Silvestre Oltra; Adela Cañete; Francisco Martínez; Carmen Orellana; Rosa Noguera; Sarai Palanca; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2011-06-25       Impact factor: 4.553

4.  Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study.

Authors:  Youssef Al-Tonbary; Mohamed Badr; Ahmed Mansour; Usama El Safy; Shebl Saeed; Tamer Hassan; Rasha Elashery; Rofida Nofal; Ahmad Darwish
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

5.  High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.

Authors:  Pramila Ramani; Scott Taylor; Elizabeth Miller; Emile Sowa-Avugrah; Margaret T May
Journal:  J Histochem Cytochem       Date:  2015-02-23       Impact factor: 2.479

6.  Neuroblastoma in adolescents: genetic and clinical characterisation.

Authors:  Victoria Castel; Eva Villamón; Adela Cañete; Samuel Navarro; Amparo Ruiz; Carmen Melero; Antonio Herrero; Yania Yáñez; Rosa Noguera
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

7.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

8.  Morphologic alteration of metastatic neuroblastic tumor in bone marrow after chemotherapy.

Authors:  Go Eun Bae; Yeon-Lim Suh; Ki Woong Sung; Jung-Sun Kim
Journal:  Korean J Pathol       Date:  2013-10-25

9.  TIAM1 variants improve clinical outcome in neuroblastoma.

Authors:  Elena Sanmartín; Yania Yáñez; Victoria Fornés-Ferrer; José L Zugaza; Adela Cañete; Victoria Castel; Jaime Font de Mora
Journal:  Oncotarget       Date:  2017-07-11

10.  Two independent epigenetic biomarkers predict survival in neuroblastoma.

Authors:  Yania Yáñez; Elena Grau; Virginia C Rodríguez-Cortez; David Hervás; Enrique Vidal; Rosa Noguera; Miguel Hernández; Vanessa Segura; Adela Cañete; Ana Conesa; Jaime Font de Mora; Victoria Castel
Journal:  Clin Epigenetics       Date:  2015-02-27       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.